T
Thomas M. Fischer
Researcher at University of Bayreuth
Publications - 122
Citations - 6849
Thomas M. Fischer is an academic researcher from University of Bayreuth. The author has contributed to research in topics: Magnetic field & Paramagnetism. The author has an hindex of 36, co-authored 120 publications receiving 6586 citations. Previous affiliations of Thomas M. Fischer include Ludwig Maximilian University of Munich & Florida State University.
Papers
More filters
Journal ArticleDOI
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Wolfgang Hiddemann,Michael Kneba,Martin Dreyling,Norbert Schmitz,Eva Lengfelder,Rudolf Schmits,Marcel Reiser,Bernd Metzner,Harriet Harder,Susanna Hegewisch-Becker,Thomas M. Fischer,Martin Kropff,Hans-Edgar Reis,Mathias Freund,Bernhard Wörmann,Roland Fuchs,Manfred Planker,Jörg Schimke,Hartmut Eimermacher,Lorenz Trümper,Ali Aldaoud,Reza Parwaresch,Michael Unterhalt +22 more
TL;DR: Adding rituximab to CHOP significantly improves the outcome for patients with previously untreated advanced-stage FL and does not induce major adverse effects.
Journal ArticleDOI
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Charles L. Sawyers,Andreas Hochhaus,Eric J. Feldman,John M. Goldman,Carole B. Miller,Oliver G. Ottmann,Charles A. Schiffer,Moshe Talpaz,François Guilhot,Michael W. Deininger,Thomas M. Fischer,S. O'Brien,Richard Stone,Carlo Gambacorti-Passerini,Nigel H. Russell,Jose J. Reiffers,Thomas C. Shea,Bernard Chapuis,Steven Coutre,Sante Tura,Enrica Morra,Richard A. Larson,Alan Saven,Christian Peschel,Alois Gratwohl,Franco Mandelli,Monique Ben-Am,Insa Gathmann,Renaud Capdeville,Ronald Paquette,Brian J. Druker +30 more
TL;DR: It is demonstrated that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis and additional clinical studies are warranted to explore the efficacy and feasibility of imatinIB used in combination with other antileukemic drugs.
Journal ArticleDOI
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Moshe Talpaz,Richard T. Silver,Brian J. Druker,John M. Goldman,Carlo Gambacorti-Passerini,Francois Guilhot,Charles A. Schiffer,Thomas M. Fischer,Michael W. Deininger,Anne L. Lennard,Andreas Hochhaus,Oliver G. Ottmann,A Gratwohl,Michele Baccarani,Richard Stone,S Tura,François Xavier Mahon,Sofia Fernandes-Reese,Insa Gathmann,Renaud Capdeville,Hagop M. Kantarjian,Charles L. Sawyers +21 more
TL;DR: Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase, and a daily dose of 600 mg is more effective than 400 mg, with similar toxicity.
Journal ArticleDOI
Microrheology and light transmission of blood. III. The velocity of red cell aggregate formation.
TL;DR: Blood from pregnant women at term, known for its pronounced red cell aggregation, shows a dissociation between the formation of short primary rouleaux and secondary RCA, which is correlated to the kinetics of red cell aggregate formation.
Journal ArticleDOI
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
Thomas Kindler,Frank Breitenbuecher,Andreas H. Marx,Joachim Beck,Georg Hess,Birgit Weinkauf,Justus Duyster,Christian Peschel,Charles James Kirkpatrick,Matthias Theobald,Harald Gschaidmeier,Christoph Huber,Thomas M. Fischer +12 more
TL;DR: Although some of the responses derived from relatively small reductions in leukemic blasts and may be attributable, in part, to prior chemotherapy, these cases suggest that imatinib has interesting clinical activity in a subset of patients with c-kit-positive AML.